Xilio Therapeutics Inc (XLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,128 | -17,203 | -76,404 | -58,749 | -42,001 |
| Depreciation Amortization | 888 | 443 | 1,900 | 1,451 | 991 |
| Accounts payable and accrued liabilities | 204 | -305 | -2,063 | -1,625 | -2,167 |
| Other Working Capital | 35,724 | 6,207 | -2,346 | -2,894 | -5,594 |
| Other Operating Activity | 3,763 | 356 | 10,293 | 6,624 | 6,947 |
| Operating Cash Flow | $9,451 | $-10,502 | $-68,620 | $-55,193 | $-41,824 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -21 | N/A | -486 | -486 | -486 |
| Investing Cash Flow | $-21 | $N/A | $-486 | $-486 | $-486 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3,375 | -3,354 | -6,752 | -5,064 | -2,820 |
| Common Stock Issued | 6,859 | 4,308 | 202 | 148 | 140 |
| Other Financing Activity | 17,513 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $20,997 | $954 | $-6,550 | $-4,916 | $-2,680 |
| Beginning Cash Position | 46,291 | 46,291 | 121,947 | 121,947 | 121,947 |
| End Cash Position | 76,718 | 36,743 | 46,291 | 61,352 | 76,957 |
| Net Cash Flow | $30,427 | $-9,548 | $-75,656 | $-60,595 | $-44,990 |
| Free Cash Flow | |||||
| Operating Cash Flow | 9,451 | -10,502 | -68,620 | -55,193 | -41,824 |
| Capital Expenditure | -21 | N/A | -486 | -486 | -486 |
| Free Cash Flow | 9,430 | -10,502 | -69,106 | -55,679 | -42,310 |